GlassScriptPhysician profile
Shyamala Kumar
NPI 1457314841
$15,359.52
in general payments reported to CMS, 2019-2025
62 companies · $3,106 in 2025
The $3,106 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,425 · 2020: $565 · 2021: $2,835 · 2022: $1,741 · 2023: $2,457 · 2024: $3,230 · 2025: $3,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,506 · Consulting Fee: $175 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,506.26 |
| Consulting Fee | $175.00 |
| Education | $112.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,594.98 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Biogen, INC. | $1,338.51 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Abbvie INC. | $1,143.98 | 2021-2025 | |
| Sk Life Science, INC. | $1,130.15 | 2020-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $1,078.49 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $990.31 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $666.40 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Pfizer INC. | $585.02 | 2019-2025 | |
| Lilly USA, LLC | $474.86 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Argenx US, INC. | $448.50 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $420.16 | 2021-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $378.43 | 2019-2025 | Rytary, Crexont |
| Eisai INC. | $355.37 | 2021-2025 | |
| Celgene Corporation | $349.53 | 2021-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $345.86 | 2019-2025 | Ingrezza, Ongentys |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyamala Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.